Luteolin ameliorated hyperglycemia and improved hypoinsulinemia, β-cell dysfunction, and renal impairment in HFD-STZ-induced diabetic rats by attenuating inflammation and dysregulated cytokine secretion through modulation of PPAR-γ, TNF-α, IL-6, and NF-kB expression and down-regulation of SREBP-1c [38]. The gene discussed is PPARG; the disease is Hyperglycemia.